Peer review reports
From: Remimazolam protects the liver from ischemia-reperfusion injury by inhibiting the MAPK/ERK pathway
Original Submission | ||
---|---|---|
25 Jan 2024 | Submitted | Original manuscript |
Resubmission - Version 2 | ||
Submitted | Manuscript version 2 | |
Resubmission - Version 3 | ||
Submitted | Manuscript version 3 | |
26 Feb 2024 | Reviewed | Reviewer Report - Jianhua Li |
10 Mar 2024 | Reviewed | Reviewer Report |
7 Apr 2024 | Author responded | Author comments - Zhiqin Zeng |
Resubmission - Version 4 | ||
7 Apr 2024 | Submitted | Manuscript version 4 |
26 Apr 2024 | Author responded | Author comments - Zhiqin Zeng |
Resubmission - Version 5 | ||
26 Apr 2024 | Submitted | Manuscript version 5 |
1 May 2024 | Reviewed | Reviewer Report |
19 Jun 2024 | Author responded | Author comments - Zhiqin Zeng |
Resubmission - Version 6 | ||
19 Jun 2024 | Submitted | Manuscript version 6 |
Publishing | ||
15 Jul 2024 | Editorially accepted | |
25 Jul 2024 | Article published | 10.1186/s12871-024-02641-3 |